

Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Nicotine

August 2022

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

This guidance, which interprets the Agency’s regulations on bioequivalence at 21 CFR part 320, provides product-specific recommendations on, among other things, the design of bioequivalence studies to support abbreviated new drug applications (ANDAs) for the referenced drug product. FDA is publishing this guidance to further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval for generic versions of this product.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

In January 2016, FDA issued a draft product-specific guidance for industry on generic nicotine. We are now issuing revised draft guidance for industry that replaces the previously issued guidance.

Active Ingredient:	Nicotine
Dosage Form; Route:	Spray, metered; nasal
Strength:	0.5 mg/spray
Recommended Studies:	Two options: (1) in vitro bioequivalence studies or (2) one in vivo bioequivalence study with pharmacokinetic endpoints

FDA recommends the following in vitro or in vivo studies to establish bioequivalence of the test (T) and reference (R) nasal sprays containing nicotine.

I. Option 1: In vitro bioequivalence studies

If the T product formulation is qualitatively (Q1)¹ and quantitatively (Q2)² the same as the R product formulation, and the nasal spray device (e.g., pump and actuator design) of the T product is appropriate for an ANDA, bioequivalence of the T nicotine nasal spray product to the R nicotine nasal spray product can be established solely by in vitro performance tests in lieu of a pharmacokinetic bioequivalence study. FDA recommends that prospective applicants conduct the following in vitro bioequivalence studies on samples from each of three or more batches of the T product and three or more batches of the R product, with no fewer than 10 units from each batch. FDA recommends that three primary stability batches be also used to demonstrate in vitro bioequivalence. The three batches of the T product should be manufactured from, at minimum, three different batches of the drug substance, three different batches of critical excipients, and three different batches of the device components (e.g., pump and actuator) proposed for the final device configuration of the commercial product. The T product should consist of the final device constituent part and final drug constituent formulation intended to be marketed. The following in vitro bioequivalence tests are recommended:

1. Single actuation content
2. Droplet size distribution by laser diffraction
3. Drug in small particles/droplets
4. Spray pattern
5. Plume geometry
6. Priming and Repriming

Additional comments: Refer to the most recent version of FDA product-specific guidance on *Fluticasone Propionate Nasal Spray Metered* (NDA 020121)^a for recommendations on design and equivalence criteria for the aforementioned in vitro bioequivalence studies, and general recommendations on the conduct of the in vitro bioequivalence studies and data submission.

II. Option 2: One in vivo bioequivalence study with pharmacokinetic endpoints

If the T formulation is not Q1 and Q2 the same as the R formulation and the nasal spray device (e.g., pump and actuator design) of the T product is appropriate for an ANDA, the following pharmacokinetic study is recommended to establish bioequivalence between the T and R product:

1. Type of study: Fasting
Design: Single-dose, two-way crossover
Strength: 0.5 mg/spray
Dose: 1.0 mg (one spray in each nostril)
Subjects: Adult males and non-pregnant, non-lactating females, general population, naïve to nicotine-containing products

¹ Q1 (qualitative sameness) means that the T product uses the same inactive ingredient(s) as the R product.

² Q2 (quantitative sameness) means that concentrations of the inactive ingredient(s) used in the T product are within $\pm 5\%$ of those used in the R product.

Additional comments: Subjects should adhere to R product labeling for drug product administration. The analytical method should have sufficient sensitivity to adequately quantify the concentration of nicotine in plasma.

Analyte to measure: Nicotine in plasma

Equivalence based on: AUC and C_{max} for nicotine. The 90% confidence interval for the geometric mean T/R ratios of C_{max} and AUC should fall within the limits of 80.00 - 125.00%.

Additional information:

Device:

The reference listed drug (RLD) product is presented in a nasal pump dispenser that is a device constituent.

FDA recommends that prospective applicants examine the size and shape, external critical design attributes, and external operating principles of the RLD device when designing the test device including the following characteristics:

- Metered, multi-dose format of RLD device
- Number of doses

User Interface Assessment:

An ANDA for this product should include complete comparative analyses so FDA can determine whether any differences in design for the user interface of the proposed generic product, as compared to the RLD, are acceptable and whether the product can be expected to have the same clinical effect and safety profile as the RLD when administered to patients under the conditions specified in the labeling. For additional information, refer to the most recent version of the FDA guidance for industry on *Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA*.^b

Revision History: Recommended January 2016; Revised August 2022

Unique Agency Identifier: PSG_020385

^a For the most recent version of the product-specific guidance, check the FDA product-specific guidance web page at: <https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm>.

^b For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.